Gilead Sciences, Inc. (GILD) Finalizes Agreement with Tibotec Pharmaceuticals Ltd to Develop and Commercialize a Single-Tablet Regimen of Prezista® with Emtriva®, GS 7340 and Cobicistat  
11/16/2011 10:31:41 AM

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a license agreement with Tibotec Pharmaceuticals for the development and commercialization of a single-tablet regimen combining Prezista® (darunavir) with Gilead’s Emtriva® (emtricitabine); its investigational agent GS 7340, a novel prodrug of tenofovir; and cobicistat, a pharmacoenhancer.